Apella Capital LLC Grows Stock Position in Pfizer Inc. (NYSE:PFE)

Apella Capital LLC grew its position in shares of Pfizer Inc. (NYSE:PFE) by 19.4% in the 2nd quarter, HoldingsChannel.com reports. The fund owned 17,611 shares of the biopharmaceutical company’s stock after acquiring an additional 2,858 shares during the period. Apella Capital LLC’s holdings in Pfizer were worth $488,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in PFE. Olistico Wealth LLC acquired a new stake in shares of Pfizer in the second quarter valued at about $25,000. Creekmur Asset Management LLC bought a new position in Pfizer during the 4th quarter worth approximately $32,000. Trivant Custom Portfolio Group LLC lifted its holdings in Pfizer by 100.0% during the 1st quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 600 shares during the last quarter. Tennessee Valley Asset Management Partners acquired a new position in Pfizer during the 4th quarter valued at approximately $36,000. Finally, DiNuzzo Private Wealth Inc. acquired a new position in Pfizer during the 4th quarter valued at approximately $37,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on PFE. Wells Fargo & Company boosted their price target on Pfizer from $28.00 to $30.00 and gave the stock an “equal weight” rating in a research report on Wednesday, July 31st. Barclays boosted their target price on Pfizer from $30.00 to $32.00 and gave the stock an “equal weight” rating in a research report on Wednesday, July 31st. StockNews.com upgraded Pfizer from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. Daiwa Capital Markets upgraded Pfizer from a “neutral” rating to an “outperform” rating in a research note on Wednesday. Finally, Morgan Stanley boosted their target price on Pfizer from $28.00 to $29.00 and gave the company an “equal weight” rating in a research note on Thursday, May 2nd. Eight equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, Pfizer currently has a consensus rating of “Hold” and an average price target of $34.58.

Pfizer Stock Down 1.6 %

NYSE:PFE traded down $0.48 on Wednesday, hitting $28.84. The stock had a trading volume of 32,848,880 shares, compared to its average volume of 39,970,480. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.78 and a current ratio of 1.05. The stock has a market cap of $163.42 billion, a P/E ratio of -491.33, a price-to-earnings-growth ratio of 1.07 and a beta of 0.69. Pfizer Inc. has a 1 year low of $25.20 and a 1 year high of $37.19. The firm’s fifty day simple moving average is $28.77 and its two-hundred day simple moving average is $27.85.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, July 30th. The biopharmaceutical company reported $0.60 EPS for the quarter, topping the consensus estimate of $0.46 by $0.14. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.31%. The company had revenue of $13.28 billion during the quarter, compared to the consensus estimate of $12.96 billion. During the same period last year, the firm earned $0.67 EPS. Pfizer’s revenue for the quarter was up 2.1% on a year-over-year basis. Analysts predict that Pfizer Inc. will post 2.68 earnings per share for the current year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 3rd. Investors of record on Friday, July 26th will be given a $0.42 dividend. This represents a $1.68 dividend on an annualized basis and a yield of 5.83%. The ex-dividend date of this dividend is Friday, July 26th. Pfizer’s payout ratio is presently -2,800.00%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.